Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Gemcitabine in HRPC
NCT00115635Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and docetaxel in prostate cancer (PCa), sponsored by Herlev Hospital. Primary endpoint: Prostate-specific antigen response. Started Mar 2005; status: completed.
02
Drugs
gemcitabinedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00115635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115635.